ArticleAAPS PharmSciTech2026
Formulation and Characterization of Amisulpride-Poly (Lactic-Co-Glycolic Acid) Nanoparticles Coated with Chitosan for Intranasal Delivery.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intranasal Biodegradable Nanomedicine for Epilepsy Management: Targeting the Brain Beyond the Blood-Brain Barrier.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amisulpride effectively treats both positive and negative symptoms of schizophrenia. However, its poor aqueous solubility and low intestinal permeability limit oral bioavailability. This study developed chitosan-coated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) encapsulating amisulpride for intranasal delivery, thereby enhancing solubility, permeability, and bioavailability. Amisulpride-loaded chitosan-coated PLGA NPs were prepared using the oil-in-water emulsion-solvent evaporation method. Formulations were optimized based on particle size (PS), zeta potential (ZP), polydispersity index (PDI), entrapment efficiency (EE%), and loading capacity (LC%). The optimized formulation was characterized by Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), thermogravimetric analysis (TGA), and X-ray diffraction (XRD). The solubility, stability, mucoadhesion, in vitro drug release, and cytotoxicity were also evaluated. The optimized formulation (F2) had a PS of 246.13 ± 2.28 nm, PDI of 0.14 ± 0.03, ZP of 41.04 ± 1.76 mV, EE% of 77.87, and LC% of 24.64. Encapsulating the drug in the NPs increased its solubility and the stability over three months showed no significant changes in the characteristics mentioned. F2 exhibited strong mucoadhesive properties and enhanced drug release at pH 5.5 and pH 7.4, with cumulative release of 77.41% at pH 7.4 and 92.17% at pH 5.5. Cytotoxicity testing confirmed biocompatibility across 0.75-10 mg/mL. Amisulpride chitosan-coated PLGA NPs demonstrated favourable physicochemical properties, solubility, stability, controlled drug release, and mucoadhesive profile with enhanced cell viability at specific concentrations across multiple epithelial cell lines compared with the drug solution and unloaded NPs. This work highlights the promising potential of Amisulpride Chitosan-coated PLGA NPs as an innovative intranasal nanocarrier for improved schizophrenia therapy.
Indexed as
Identifiers
41872643What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.